AG’s opinion on interpretation of SPC Regulation in Teva v Gilead


Although SPCs have a relatively short term (five years maximum) they can be extremely valuable to innovator companies. As much as 80% of the total revenue for a particular medicine can be generated during the lifetime of the SPC.
Laura Reynolds discusses conditions for obtaining an SPC, current references to CJEU and AG’s opinion in Teva v Gilead in Intellectual Property Magazine.
The full version is available to read via subscription on the Intellectual Propery Magazine website.

Related Articles